Compare stocks

Evaluate stocks side by side, to find the best fit for your investment goals.
ChemoMetec A/S is engaged in the development, manufacturing, and marketing of analytical instruments used for counting and analyzing cells in a variety of applications across biotechnology, pharmaceuticals, and academic research sectors. The company’s main product lines include automated cell counters and analyzers, such as the NucleoCounter series. Founded in 1997, ChemoMetec is headquartered in Allerod, Denmark. The company is noted for its focus on innovation in cell counting technology, providing precise and user-friendly solutions that facilitate laboratory workflows and enhance data accuracy. Its strategic position in the analytical instruments industry is strengthened by its commitment to quality and reliability in measurement instrumentation.
View stock
VS
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with Imbruvica and Venclexta). The company was spun off from Abbott in early 2013. The 2020 acquisition of Allergan added several new products and drugs in aesthetics, including Botox. The 2024 acquisitions of Cerevel (neuroscience) and ImmunoGen (oncology) help supplement AbbVie's portfolio.
View stock

Stock highlights

Stock comparison highlights
Stock name
ChemoMetec A/SAbbVie
Last price
€79.43$285.84
Currency
EUR
USD
€1.4B$504B
51.2680.57
€1.55$3.54
1.390.28
0$6.83
02.43%
Sector
HealthHealth
Employees
17457,000
Ticker
€CHEMM$ABBV
Primary listing
XGATNYSE

Performance

CumulativeRolling yearsLump sum investment

Invest in €CHEMM or $ABBV on Lightyear

Save on broker fees and invest in 6000+ stocks and funds. When you invest, your capital is at risk.